Llwytho...
Advances in First-Line Treatment for Patients with HER-2(+) Metastatic Breast Cancer
BACKGROUND. The prognosis for breast cancer patients overexpressing human epidermal growth factor receptor (HER)-2 has changed with anti–HER-2–targeted therapy. Although anti–HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AlphaMed Press
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3360903/ https://ncbi.nlm.nih.gov/pubmed/22523199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0187 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|